Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis

NCT00630864 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00630864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00630864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2008
Completion date
January 31, 2010
Enrollment
21 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

transthyretin-associated amyloidosis with polyneuropathy